MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout

While MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb’s Cobenfy is likely to hold its market share.